Identification of immunologic biomarkers associated with clinical response after immune-based therapy for cancer

Annals of the New York Academy of Sciences

Volumn 1174, Issue , 2009, Pages 81-87

  Dang, Yushe ^a   Disis, Mary L ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Biomarker; Clinical response; Immune; Immunotherapy

Indexed keywords

BIOLOGICAL MARKER; CARCINOEMBRYONIC ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; IMMUNOGLOBULIN G ANTIBODY; MELANOMA ANTIGEN 1; TRANSCRIPTION FACTOR FOXP3; CD3 ANTIGEN; LEUKOCYTE ANTIGEN;

CANCER DIAGNOSIS; CANCER IMMUNOTHERAPY; CELL THERAPY; CONFERENCE PAPER; ENZYME LINKED IMMUNOSPOT ASSAY; HUMAN; NONHUMAN; POLYMERASE CHAIN REACTION; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE; VALIDATION STUDY; ADOPTIVE IMMUNOTHERAPY; ANIMAL; ARTICLE; CLINICAL TRIAL; EXPERIMENTAL NEOPLASM; IMMUNOLOGY; IMMUNOTHERAPY; METHODOLOGY; MOUSE; NEOPLASM;

MURINAE;

ANIMALS; ANTIGENS, CD; ANTIGENS, CD3; BIOLOGICAL MARKERS; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOTHERAPY; IMMUNOTHERAPY, ADOPTIVE; MICE; NEOPLASMS; NEOPLASMS, EXPERIMENTAL; T-LYMPHOCYTES;

EID: 70350441897     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2009.04937.x     Document Type: Conference Paper

References (28)

1. Pepe, M.S., R. Etzioni, Z. Feng, et al. 2001. Phases of biomarker development for early detection of cancer. J. Natl. Cancer Inst. 93: 1054-1061. (Pubitemid 32717537)
2. Walker, E.B. & M.L. Disis. 2003. Monitoring immune responses in cancer patients receiving tumor vaccines. Int. Rev. Immunol. 22: 283-319. (Pubitemid 36758664)
3. McShane, L.M., D.G. Altman, W. Sauerbrei, et al. 2005. Reporting recommendations for tumor marker prognostic studies (REMARK). J. Natl. Cancer Inst. 97: 1180-1184. (Pubitemid 41258223)
4. Galon, J. A. Costes, F. Sanchez-Cabo, et al. 2006. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313: 1960-1964.
5. Kreike, B., M. van Kouwenhove, H. Horlings, et al. 2007. Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Breast Cancer Res. 9: R65. (Pubitemid 350187481)
6. Zhang, L., JR. Conejo-Garcia, D. Katsaros, et al. 2003. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. 348: 203-213. (Pubitemid 36077915)
7. Inokuma, M., C. dela Rosa, C. Schmitt, et al. 2007. Functional T cell responses to tumor antigens in breast cancer patients have a distinct phenotype and cytokine signature. J. Immunol. 179: 2627-2633.
8. Goodell, V., L.G. Salazar, N. Urban, et al. 2006. Antibody immunity to the p53 oncogenic protein is a prognostic indicator in ovarian cancer. J. Clin. Oncol. 24: 762-768. (Pubitemid 46622043)
9. Butterfield, L.H., A. Ribas, V.B. Dissette, et al. 2003. Determinant spreading associated with clinical re-sponse in dendritic cell-based immunotherapy for malignant melanoma. Clin. Cancer Res. 9: 998-1008.
10. Salazar, L., V. Goodell, M. O'Meara, et al. 2009. Persistent immunity and survival after immunization with a HER-2/neu (HER2) vaccine. J. Clin. Oncol. 27: 3010.
11. Salama, P., M. Phillips, F. Grieu, et al. 2009. Tumorinfiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. J. Clin. Oncol. 27: 186-192.
12. Schreiber, T.H. 2007. The use of FoxP3 as a biomarker and prognostic factor for malignant human tumors. Cancer Epidemiol. Biomarkers Prev. 16: 1931-1934.
13. Disis, M.L., D. Wallace, TA. Gooley, et al. 2009. Concurrent trastuzumab and HER-2/neu specific vaccination in patients with metastatic breast cancer. J. Clin. Oncol. in press.
14. Herschkowitz, J.I., K. Simin, V.J. Weigman, et al. 2007. Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol. 8: R76.
15. Lu, H., K.L. Knutson, E. Gad & M.L. Disis. 2006. The tumor antigen repertoire identified in tumor-bearing neu transgenic mice predicts human tumor antigens. Cancer Res. 66: 9754-9761. (Pubitemid 44623677)
16. Roberts, R.B., C.L. Arteaga & D.W. Threadgill. 2004. Modeling the cancer patient with genetically engineered mice: prediction of toxicity from molecule-targeted therapies. Cancer Cell. 5: 115-120.
17. Cipriani, B., A. Fridman, C. Bendtsen, et al. 2008. Therapeutic vaccination halts disease progression in BALB-neuT mice: the amplitude of elicited immune response is predictive of vaccine efficacy. Hum. Gene Ther. 19: 670-680. (Pubitemid 352009912)
18. Driessens, G., L. Gordower, L. Nuttin, et al. 2008. Therapeutic efficacy of antitumor dendritic cell vaccinations correlates with persistent Th1 responses, high intratumor CD 8+ T cell recruitment and low relative regulatory T cell infiltration. Cancer Immunol. Immunother. 57: 1745-1756.
19. Atkins, M.B., D. Carbone, G. Coukos, et al. 2007. Report on the ISBTC mini-symposium on biologic effects of targeted therapeutics. J. Immunother. 30: 577-590.
20. Cheever, M.A. & W. Chen. 1997. Therapy with cultured T cells: principles revisited. Immunol. Rev. 157: 177-194.
21. Disis, M., L. Salazar, A. Coveler, et al. 2009. Phase I study of infusion of HER-2/neu (HER2) specific T cells in patients with advanced stage HER2 overexpressing cancers who have received a HER2 vaccine. J. Clin. Oncol. 27: 3000.
22. Dudley, M.E., J.C. Yang, R. Sherry, et al. 2008. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J. Clin. Oncol. 26: 5233-5239.
23. Zhou, J., X. Shen, J. Huang, et al. 2005. Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy. J. Immunol. 175: 7046-7052. (Pubitemid 41598952)
24. Hunder, N.N., H. Wallen, J. Cao, et al. 2008. Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N. Engl. J. Med. 358: 2698-2703.
25. Dang, Y., L. Salazar, A. Coveler, et al. 2009. Phase 1 study of infusion of HER-2/neu specific T cells in patients with advanced stage HER-2/neu over-expressing cancers who have re-ceived a HER-2/neu vaccine. J. Immunol. 182: 41.3.
26. Robbins, P.F., M.E. Dudley, J. Wunderlich, et al. 2004. Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy. J. Immunol. 173: 7125-7130.
27. Dudley, M.E., J.R. Wunderlich, P.F. Robbins, et al. 2002. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298: 850-854.
28. Bernhard, H., J. Neudorfer, K. Gebhard, et al. 2008. Adoptive transfer of autologous, HER2-specific, cytotoxic T lymphocytes for the treatment of HER2-overexpressing breast cancer. Cancer Immunol. Immunother. 57: 271-280. (Pubitemid 350159915)